(Q38041271)

27 August 2017

title

Assessing commercial opportunities for autologous and allogeneic cell-based products (English)

1 reference

27 August 2017

Devyn M Smith

1

1 reference

27 August 2017

language of work or name

1 reference

1 September 2012

1 reference

27 August 2017

published in

Regenerative Medicine

1 reference

27 August 2017

volume

7

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

721-732

1 reference

Cell therapy industry: billion dollar global business with unlimited potential.

27 August 2017

cites work

1 reference

Assessing the value of autologous and allogeneic cells for regenerative medicine

21 January 2018

1 reference

Process economics of industrial monoclonal antibody manufacture

21 January 2018

1 reference

Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction

21 January 2018

1 reference

10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice

21 January 2018

1 reference

Cardiac cell therapy: lessons from clinical trials

21 January 2018

1 reference

Autologous transplantation of blood-derived stem/progenitor cells for ischaemic heart disease

21 January 2018

1 reference

Stem cell therapy for heart diseases

21 January 2018

1 reference

21 January 2018

Critical limb ischemia

1 reference

Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia?

21 January 2018

1 reference

Treatment of peripheral arterial disease using stem and progenitor cell therapy.

21 January 2018

1 reference

Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/RME.12.40

1 reference

27 August 2017

1 reference